An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians
about
sameAs
Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2CsClinical relevance of genetic polymorphisms in the human CYP2C subfamilyEvaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay)Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents.Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues.In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestaneThe influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Advancing the medical management of epilepsy: disease modification and pharmacogenetics.New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card systemCurrent State and Future Prospects of Direct-to-Consumer PharmacogeneticsMolecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized MedicineClinical application of pharmacogenetics in gastrointestinal diseases.Sex-specific differences in CYP450 isoforms in humans.PhRMA white paper on ADME pharmacogenomics.Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.The role of pharmacogenetics in nonmalignant gastrointestinal diseases.Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population.The Affymetrix DMET Plus platform reveals unique distribution of ADME-related variants in ethnic Arabs.Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.
P2860
Q28144397-AC38F66A-CE18-421E-BC61-70A055617623Q28362533-5A764172-F628-4F5D-A6A8-D916B289264EQ33261407-30C7FC26-1CAE-442F-A122-E896B57FABD1Q33355914-443A357A-5C94-4E9E-901A-9753E36FA7B9Q33639778-D3A12719-5B6E-4504-B180-66007140215EQ33777963-6277D043-9BD7-4439-9D86-08AEA88FDF9AQ33875640-A863E01D-B70B-45FD-AE83-BBEC942A7AEFQ34307589-A7056D85-E6F5-4562-88FB-9998E88892F0Q34579490-90143A7F-C519-4681-A307-1A8D63041C97Q34994964-1EB3DEF2-AF19-4F5E-9C76-DA4A81E61FCBQ35873687-96FCE567-1C2A-448B-8296-6F3666A03FD6Q35952367-E4EC9D0C-EE85-446E-A250-91E0C40A580EQ36053568-2901123C-D9C4-44D8-ACFC-162CD9959DB2Q36053911-C714A8A1-A391-4232-813B-5836BEAEB162Q36055226-D0A9E337-6803-4B9E-81A7-252DAB03CA04Q36174824-DD10F6B4-8609-4984-B075-71992D302B9BQ36307008-3477CD75-F672-4DF2-8EFA-52028A9D1F03Q36580034-8FDBCF76-A943-48E5-82B5-AFCD3EFEC356Q36613862-A0EB90B6-4A08-4332-8D32-B2C04479C48FQ37181876-DB8B0B06-12B2-42B1-AA31-7CE036BFCD1DQ37182212-032D7390-3877-4DF8-BFA6-E000DE0DF2EEQ37964573-F421B5FC-0F9F-4819-80B4-E5B729F0D94FQ37981892-3A9EFC2E-891F-4D2F-BD8A-32B2A830445BQ41432957-433BFCF8-CEDE-447B-A3E9-76EE33F98E9CQ42204185-8044E698-842B-4EEE-8E41-B48B73BD7339Q46724143-7A9817F5-03C3-433F-A918-77EEE9CBB09BQ47554139-9C582EAB-5AFE-42E6-BA58-23BF34FB35D6Q49925445-DCA2F641-E22B-4C1B-9C54-1D9B3E3D8EFF
P2860
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
An additional defective allele ...... olizer phenotype in Caucasians
@ast
An additional defective allele ...... olizer phenotype in Caucasians
@en
An additional defective allele ...... olizer phenotype in Caucasians
@nl
type
label
An additional defective allele ...... olizer phenotype in Caucasians
@ast
An additional defective allele ...... olizer phenotype in Caucasians
@en
An additional defective allele ...... olizer phenotype in Caucasians
@nl
prefLabel
An additional defective allele ...... olizer phenotype in Caucasians
@ast
An additional defective allele ...... olizer phenotype in Caucasians
@en
An additional defective allele ...... olizer phenotype in Caucasians
@nl
P2093
P1476
An additional defective allele ...... olizer phenotype in Caucasians
@en
P2093
B I Ghanayem
C Bouchardy
G C Ibeanu
G R Wilkinson
J A Goldstein
J Blaisdell
S Benhamou
P304
P356
10.1097/00008571-199804000-00006
P407
P577
1998-04-01T00:00:00Z